Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Pfizer Inc.    PFE   US7170811035

PFIZER INC. (PFE)

404
Delayed Quote. Delayed Nyse - 07/01 04:00:09 pm
33.69 USD   +0.48%
06:52a PFIZER : NIHR Clinical Research Network to INSPIRE clinical trial ac..
06/29 Bank controls add to headaches for Greece's pharmacists
06/29 DOW MOVERS : Jpm, pfe
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

11/19/2012 | 08:40am US/Eastern
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
React to this article
Latest news on PFIZER INC.
02:56p PFIZER : Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell D..
02:14p PFIZER : CDC Advisory Committee on Immunization Practices Votes to Recommend Ser..
01:53p PFIZER : Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithK..
12:59p PFIZER : Joseph J. Echevarria Elected To Pfizer's Board Of Directors
06:52a PFIZER : NIHR Clinical Research Network to INSPIRE clinical trial access for UK ..
06/30 PFIZER : Elects Joseph Echevarria to Its Board
06/29 Bank controls add to headaches for Greece's pharmacists
06/29 DOW MOVERS : Jpm, pfe
06/29 Drugmakers warn Greek medicine supply 'may be in jeopardy'
06/28 PFIZER : GlycoMimetics to Purchase Payment from Pfizer Following Initiation of P..
Advertisement
Chart
Duration : Period :
Pfizer Inc. Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Income Statement Evolution
More Financials